VivaVision and Jiangxi Shanliang Pharmaceutical formed a strategic alliance to enhance contact lens care products, while QurAlis entered an exclusive license agreement with Eli Lilly for the development of a promising treatment for neurodegenerative diseases.
Target Information
VivaVision Biotech is a clinical-stage pharmaceutical company dedicated to advancing best-in-class and first-in-class therapies specifically for ocular diseases. Its current product pipeline features VVN001, designed to treat dry eye syndrome, VVN539, intended for the treatment of Glaucoma and Ocular Hypertension, and VVN461, which targets non-infectious ocular inflammation associated with Uveitis. Additionally, VivaVision actively focuses on the discovery and development of innovative treatments for a range of anterior and posterior eye diseases.
Recently, VivaVision has made notable progress with its portfolio companies, signaling its commitment to technological innovation and collaboration within the biopharmaceutical sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The biopharmaceutical industry in China has been experiencing rapid growth and transformation, driven by increasing healthcare needs and significant investments in biotech innovations. The country's ongoing commitment to improving healthcare infrastructure and poli
Similar Deals
VivaVision
invested in
Jiangxi Shanliang Pharmaceutical Co., Ltd.
in 2024
in a Joint Venture deal
Disclosed details
Transaction Size: $45M
Revenue: $99M
EBITDA: $54M
EBIT: $32M
Net Income: $21M
Enterprise Value: $622M
Equity Value: $235M
Multiples
EV/EBITDA: 11.5x
EV/EBIT: 19.4x
EV/Revenue: 6.3x
P/E: 11.2x
P/Revenue: 2.4x